Debate Series - Estro-events.org

E-posTErs
E-Posters
CliniCal inTERdiSCiPlinaRy PhySiCS RadiObiOlOgy RTT yOung
Page 254 PROgRammE & ExhibiTiOn guidE • ESTRO 31
abS. numbER
> Helical Tomotherapy in the treatment of anal cancer: the lausanne
experience
H. Bouchaab (Switzerland), O. Matzinger, P. Tsoustou, S. Peters,
M. Pachoud, R.O. Mirimanoff, M. Ozsahin EP-1074
> Primary conformal radiotherapy and chemotherapy for esophageal
cancer: preliminary results of a randomized trial
M. Ibraimova (Kazakhstan), V. Kim, T. Antropova, R. Abdrakhmanov,
A. Almabek, Y. Ishkinin, O. Truschenko, Y. Malysheva EP-1075
> Effect of neoadjuvant chemotherapy and high dose conformal
radiotherapy in T3-4 and/or N positive anal cancer
A.R. Jensen (Denmark), M.M. Fode, J.C. Lindegaard, S. Buntsen,
L. Lundby EP-1076
> Combined modality treatment in anal canal carcinoma: impact of
full dose treatment and clinical stage category
S. Solé (Chile), C. Solé, V. Ovalle, M. Russo, M. Baeza EP-1077
> Postoperative gastric cancer chemoradiation: long term results
with CTV definition based on tumor site and p-Stage
V. Picardi (Italy), R. Tambaro, G. Macchia, F. Deodato, S. Mignogna,
G. Cecere, F. Pacelli, V. Valentini, N. Cellini, A.G. Morganti EP-1078
> Role of neoadjuvant chemoradiation in locally advanced
unresectable gall bladder cancers
R. Engineer (India), M. Goel, S. Mehta, S.V. Shrikhande, P. Patil,
S. Chopra, V. Rangarajan, N. Purandare, S.K. Shrivasatava EP-1079
> FDG-PET SUV and biological markers as predictive factors of
tumour response in anal canal cancer treated with RT-CT
M. Krengli (Italy), M.E. Milia, L. Deantonio, L. Turri, G. Loi,
G. Sacchetti, R. Boldorini, E. Maldi, T. Cena, C. Magnani EP-1080
> Loco-regional control after radiochemotherapy for anal cancer:
a single centre retrospective analysis
F. Zehentmayr (Germany), M.C. Wolf, M.E. Kreis, C. Belka EP-1081
E-Posters
abS. numbER
> Role of pretreatment CEA level in patients with rectal cancer
receiving preoperative chemoradiotherapy
S. Yeo (Korea Republic of), D. Kim EP-1082
> Adjuvant radiochemotherapy in cholangiocarcinoma may improve
overall survival after surgery
M. Pazos (Germany), F. Zehentmayr, M. Wolf, W. Haimerl,
M. Rentsch, V. Heinemann, C. Belka EP-1083
> Phase II study of helical tomotherapy in the multidisciplinary
treatment of oligometastatic colorectal cancer
B. Engels (Belgium), T. Gevaert, H. Everaert, P. De Coninck,
A. Sermeus, N. Christian, G. Storme, D. Verellen, M. De Ridder EP-1084
> Acute toxicity after a diverting stoma and spacer prior to chemoradiation
in locally advanced rectal cancer
J.R.N. Van der Voort van Zyp (The Netherlands), H. Ceha, V. Niehe,
H. Putter, A. Marinelli, C. Marijnen EP-1085
> Extrahepatic bile duct cancer: analysis of treatment outcomes and
patterns of failure
T.R. Koo (Korea Republic of), J.S. Kim EP-1086
> Results from a phase II non randomized trial on 145 patients with
hepato-cellular carcinoma with VMAT
P. Wang (Taiwan), W.C. Hsu, N.N. Chung, F.L. Chang, E. Vanetti,
G. Nicolini, A. Fogliata, L. Cozzi EP-1087
> Preoperative adaptive tomotherapy concomitant to chemotherapy
in rectal cancer: early results of phase I/II study
N. Slim (Italy), N.A. Iacovelli, S. Brenna, P. Passoni, C. Fiorino,
S. Broggi, V. Ricci, F. De Cobelli, R. Calandrino, N. Di Muzio EP-1088
> Proton therapy for pancreatic and ampullary cancer is associated
with a low incidence of gastrointestinal toxicity
R. Nichols (USA), T. George, R. Zaiden, S. Hochwald, Z. Awad,
M. Ho, Z. Li, N. Mendenhall, W. Mendenhall, B. Hoppe EP-1089
ESTRO 31 • PROgRammE & ExhibiTiOn guidE Page 255
E-posTErs
eSTRO 31